The ATX and LPA receptors inhibitor BrP-LPA we used has also been studied in A549 non-small cell lung cancer [27] and MDA-MB-231 breast cancer [38] cells at doses ranging from 10 to 40 μM, but its effects have never been studied in endothelial cells or in conjunction with radiation. Here, LPA is linked to breast carcinoma.